| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC67420 | AZD2389 Featured | AZD2389 represents a novel, orally bioavailable fibroblast activation protein (FAP) inhibitor with significant therapeutic potential. |
|
| DC67421 | Enozertinib Featured | Enozertinib is a next-generation EGFR tyrosine kinase inhibitor demonstrating potent antineoplastic effects against EGFR-driven malignancies. |
|
| DC67422 | Alixorexton( ALKS 2680) Featured | Alixorexton is a selective orexin-2 receptor (OX2R) agonist demonstrating significant metabolic modulation potential. |
|
| DC67423 | BMS-986238 Featured | BMS-986238 represents an advanced macrocyclic peptide therapeutic that demonstrates potent and selective inhibition of PD-L1 immune checkpoint signaling. |
|
| DC67424 | RP-1664 Featured | RP-1664 is a novel, orally bioavailable inhibitor that selectively targets polo-like kinase 4 (PLK4) with high potency. |
|
| DC67425 | BMS-986458 Featured | BMS-986458 represents a breakthrough in targeted protein degradation as a first-in-class, orally available PROTAC® molecule that specifically degrades B-cell lymphoma 6 (BCL6). |
|
| DC67426 | PRT3789 Featured | PRT3789 is a first-in-class proteolysis-targeting chimera (PROTAC) that selectively degrades SMARCA2 (BRM) while exhibiting minimal activity against its closely related paralog SMARCA4 (BRG1). |
|
| DC67427 | FG-2101 Featured | FG-2101 represents a next-generation antibacterial agent as a potent, orally bioavailable non-hydroxamate inhibitor of LpxC – a key enzyme in Gram-negative bacterial lipopolysaccharide biosynthesis. |
|
